KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial.

Martin Langé, Loïc Campion, Luc Ollivier, Marion Renouf, Nicolas Magné, Igor Latorzeff, Pascal Pommier, Etienne Martin, Amaury Paumier, Guillaume Bera, Charles Catton, Jarad Martin, Stephane Supiot

Int J Radiat Oncol Biol Phys 122(2) 399-406

PMID39914555
PMCID-
DOI10.1016/j.ijrobp.2025.01.030
发表日期2025-02-06
入排依据:The study is a Phase III randomized trial with time-to-event endpoints, but the intervention is radiation therapy (hypofractionated vs. conventional), not a drug-containing intervention. Therefore, it does not meet the eligibility criterion for a drug intervention.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: Conventionally fractionated radiation therapy (CFRT) and hypofractionated RT (HFRT) are established treatments for intermediate-risk (IR) prostate cancer (PCa), with differing dose per fraction. However, their comparative patterns of failure remain unclear. This stuy aims to analyze the distinct relapse patterns of HFRT versus CFRT in terms of local progression-free survival (LPFS), pelvic lymph node metastasis-free survival (pnMFS), extrapelvic lymph node MFS (epnMFS), and bone MFS (bMFS). METHODS AND MATERIALS: Patients with IR PCa included in French and Australian centers in the "PROstate Fractionated Irradiation Trial (PROFIT)" study (NCT00304759), a phase 3, multicenter, randomized controlled trial. Using molecular positron emission tomography imaging, magnetic resonance imaging, and bone scintigraphy, the anatomic sites of relapse were retrospectively identified in biochemically relapsing patients after HFRT or CFRT. LPFS, pnMFS, epnMFS, and bMFS were compared between both treatment arms using Kaplan-Meier analyses. RESULTS AND LIMITATIONS: With a median follow-up of 6.4 years, 274 patients (130 HFRT and 144 CFRT) were included, among whom 35 (24.3%) in the HFRT arm and 28 (19.4%) in the CFRT arm experienced relapse. Median time to relapse varied by site: 4.9 years locally, 3.96 years for pelvic lymph nodes, 2.95 years for extrapelvic lymph nodes, and 3.6 years for bone metastasis. No significant differences were found between HFRT and CFRT arms in LPFS, pnMFS, epnMFS, or bMFS. CONCLUSIONS: Relapse rates after HFRT or CFRT are low, with no discernible variance in anatomical relapse patterns between treatments. Tailored management strategies considering these relapse patterns could optimize care of IR patients, including initial staging and microboosting of dominant lesions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。